New York approves PreciseDx's AI breast cancer diagnostic
PreciseDx just secured New York State regulatory approval for PDxBr, its AI-powered diagnostic test for invasive breast cancer. The tool uses array morphology to deliver quantifiable pathology data and improve risk stratification, allowing its certified lab to begin testing live patient samples. Why it matters: It marks another concrete step toward replacing subjective manual pathology reviews with quantifiable algorithmic analysis.